MA28033A1 - Preparation pharmaceutique comprenant un derive de la pyrimidine-a-one enrobe d'un polymere enterique - Google Patents

Preparation pharmaceutique comprenant un derive de la pyrimidine-a-one enrobe d'un polymere enterique

Info

Publication number
MA28033A1
MA28033A1 MA28866A MA28866A MA28033A1 MA 28033 A1 MA28033 A1 MA 28033A1 MA 28866 A MA28866 A MA 28866A MA 28866 A MA28866 A MA 28866A MA 28033 A1 MA28033 A1 MA 28033A1
Authority
MA
Morocco
Prior art keywords
enteric polymer
pyrimidine
derived
pharmaceutical preparation
phospholipase
Prior art date
Application number
MA28866A
Other languages
English (en)
Inventor
Marinus Johannes Van Schie Dirk
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA28033A1 publication Critical patent/MA28033A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formulation pharmaceutique comprenant un dérivé de pyrimidine-A-one enrobé avec un polymère entérique La présente invention propose des formulations de comprimés enrobés avec un polymère entérique pour administration orale, qui comprennent un inhibiteur de l'enzyme phospholipase A2 consistant en la phospholipase A2 associée aux lipoprotéines (Lp-PLA2), les procédés pour la préparation de telles formulations et leur utilisation en thérapeutique, en particulier dans le traitement de l'athérosclérose.
MA28866A 2003-09-02 2006-03-10 Preparation pharmaceutique comprenant un derive de la pyrimidine-a-one enrobe d'un polymere enterique MA28033A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0320522.6A GB0320522D0 (en) 2003-09-02 2003-09-02 Formulation

Publications (1)

Publication Number Publication Date
MA28033A1 true MA28033A1 (fr) 2006-07-03

Family

ID=28686767

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28866A MA28033A1 (fr) 2003-09-02 2006-03-10 Preparation pharmaceutique comprenant un derive de la pyrimidine-a-one enrobe d'un polymere enterique

Country Status (30)

Country Link
US (2) US20060287346A1 (fr)
EP (1) EP1663243B1 (fr)
JP (1) JP4892346B2 (fr)
KR (1) KR101115984B1 (fr)
CN (2) CN1874778B (fr)
AR (1) AR045547A1 (fr)
AT (1) ATE422889T1 (fr)
AU (1) AU2004268376B2 (fr)
BR (1) BRPI0414038A (fr)
CA (1) CA2537178C (fr)
CY (1) CY1108953T1 (fr)
DE (1) DE602004019547D1 (fr)
DK (1) DK1663243T3 (fr)
ES (1) ES2319124T3 (fr)
GB (1) GB0320522D0 (fr)
HR (1) HRP20090147T3 (fr)
IL (1) IL173910A (fr)
IS (1) IS2677B (fr)
MA (1) MA28033A1 (fr)
MX (1) MXPA06002436A (fr)
MY (1) MY139165A (fr)
NO (1) NO333744B1 (fr)
NZ (1) NZ545453A (fr)
PL (1) PL1663243T3 (fr)
PT (1) PT1663243E (fr)
RU (1) RU2359660C2 (fr)
SI (1) SI1663243T1 (fr)
TW (1) TWI343257B (fr)
WO (1) WO2005021002A1 (fr)
ZA (1) ZA200601599B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320522D0 (en) * 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation
BRPI0721697A2 (pt) 2007-05-11 2014-08-05 Univ Jefferson " métodos para tratar e/ou prevenir uma doença ou distúrbio neurodegenerativo em um indivíduo, para tratar e/ou prevenir um indivíduo com ou em risco de demência vascular, para tratar e/ou prevenir uma doença ou distúrbio associado com uma barreira hematoencefálica anormal em um indivíduo, para diminuir o acúmulo beta amilóide no cérebro de um indivíduo, para tratar e/ou prevenir mal de alzheimer em um indivíduo e para prevenir ou reduzir o risco de desenvolver mal de alzhheimer, e, uso de um agente que inibe a expressão e/ou atividade da proteína lp-pla2."
US9029383B2 (en) 2007-05-11 2015-05-12 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
CA2759123C (fr) 2009-04-24 2019-01-15 Iceutica Pty Ltd Compositions d'acide de diclofenac a dissolution amelioree
EP2651403B1 (fr) 2010-12-17 2020-12-02 Glaxo Group Limited Procédés de traitement et de prévention de maladies oculaires
WO2013082275A1 (fr) 2011-11-30 2013-06-06 Trustees Of Boston College Inhibiteurs de phosphodiestérases 11 (pde11) et procédés d'utilisation pour augmenter la production de cortisol
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
EP3172211B1 (fr) 2014-07-22 2019-07-03 GlaxoSmithKline Intellectual Property Development Limited Composés tricycliques imidazopyrimidone pour le traitement de maladies à mediation lp-pla2
JP2026516205A (ja) 2023-04-18 2026-05-20 サイニューロ セラピューティクス インコーポレイテッド Ｌｐ－ｐｌａ２阻害剤と第２の薬剤の併用治療

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3619570C1 (en) 1986-06-11 1987-10-29 Kneipp Werke Kneipp Mittel Zen Coated garlic tablet
US4971805A (en) 1987-12-23 1990-11-20 Teysan Pharmaceuticals Co., Ltd. Slow-releasing granules and long acting mixed granules comprising the same
IT1227899B (it) * 1988-12-23 1991-05-14 Poli Ind Chimica Spa Rivestimento totale o parziale di principi attivi farmaceutici e relative composizioni
TW209174B (fr) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
JPH07223970A (ja) 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤
JP2917799B2 (ja) 1994-03-11 1999-07-12 田辺製薬株式会社 消化管内適所放出型製剤
JP3185206B2 (ja) * 1995-07-20 2001-07-09 田辺製薬株式会社 消化管下部放出型被覆カプセル製剤
SG80553A1 (en) 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
NZ333182A (en) * 1996-06-06 2000-03-27 Bifodan As Enteric coating comprising alginic acid and a water soluble binding agent for an oral preparation
JP2000516222A (ja) * 1996-08-15 2000-12-05 ロザン ファルマ ゲゼルシャフトミットベシュレンクテル ハフツング 嚥下が容易な経口医薬組成物
US6296876B1 (en) * 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
PT1121103E (pt) * 1998-05-18 2007-02-28 Takeda Pharmaceutical Comprimidos de desintegração oral compreendendo um benzimidazole
WO2000028989A1 (fr) 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Composition pharmaceutique a liberation modifiee d'un agent de sensibilisation a l'insuline, et d'un autre agent antidiabetique
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
DE60139429D1 (de) * 2000-02-16 2009-09-10 Smithkline Beecham Plc Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren
AUPQ672800A0 (en) * 2000-04-06 2000-05-04 Natraherbal Pty Ltd Garlic supplement for deodoriser
EP1294358B1 (fr) * 2000-06-28 2004-08-18 Smithkline Beecham Plc Procede de broyage par voie humide
JP5138856B2 (ja) * 2001-06-20 2013-02-06 武田薬品工業株式会社 錠剤の製造方法
ATE508725T1 (de) 2001-06-20 2011-05-15 Takeda Pharmaceutical Verfahren zur herstellung von tabletten
RU2203671C1 (ru) * 2002-03-25 2003-05-10 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Противовирусный лекарственный препарат для перорального применения
GB0320522D0 (en) * 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation

Also Published As

Publication number Publication date
MY139165A (en) 2009-08-28
AU2004268376B2 (en) 2010-04-22
BRPI0414038A (pt) 2006-10-24
RU2359660C2 (ru) 2009-06-27
EP1663243B1 (fr) 2009-02-18
IL173910A (en) 2010-11-30
IS8366A (is) 2006-03-20
CN1874778B (zh) 2011-06-22
TWI343257B (en) 2011-06-11
IL173910A0 (en) 2006-07-05
ATE422889T1 (de) 2009-03-15
PL1663243T3 (pl) 2009-07-31
KR20060118422A (ko) 2006-11-23
US20090306113A1 (en) 2009-12-10
NZ545453A (en) 2009-12-24
CN102204891B (zh) 2013-08-21
NO333744B1 (no) 2013-09-09
AU2004268376A1 (en) 2005-03-10
CN1874778A (zh) 2006-12-06
EP1663243A1 (fr) 2006-06-07
JP4892346B2 (ja) 2012-03-07
CY1108953T1 (el) 2014-07-02
DK1663243T3 (da) 2009-05-04
KR101115984B1 (ko) 2012-03-13
RU2006110546A (ru) 2006-08-10
NO20061514L (no) 2006-04-03
HK1091734A1 (en) 2007-01-26
HRP20090147T3 (hr) 2009-04-30
JP2007504195A (ja) 2007-03-01
US8772303B2 (en) 2014-07-08
CA2537178A1 (fr) 2005-03-10
GB0320522D0 (en) 2003-10-01
DE602004019547D1 (de) 2009-04-02
TW200517113A (en) 2005-06-01
ZA200601599B (en) 2007-05-30
SI1663243T1 (sl) 2009-06-30
PT1663243E (pt) 2009-04-27
MXPA06002436A (es) 2006-06-20
AR045547A1 (es) 2005-11-02
CA2537178C (fr) 2013-03-19
US20060287346A1 (en) 2006-12-21
ES2319124T3 (es) 2009-05-04
CN102204891A (zh) 2011-10-05
WO2005021002A1 (fr) 2005-03-10
IS2677B (is) 2010-09-15

Similar Documents

Publication Publication Date Title
MA29321B1 (fr) Vaccin a base de rotavirus vivant attenue pour administration orale
HUP0104258A2 (hu) HMG-CoA reduktáz inhibítort tartalmazó stabil gyógyszerkészítmények
MXPA05001607A (es) Forma galenica para suministro de ingredientes activos dirigido al colon.
YU49202A (sh) Benzazolski derivati i njihova upotreba kao modulatora jnk
MA30359B1 (fr) Composition pharmaceutique a liberation prolongee sur la base d'un systeme de liberation comprenant un polymere soluble dans l'acide et un polymere dependant du ph
TNSN01053A1 (fr) Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique
MA28740B1 (fr) Methodes de traitement d'infections endobronchiques
FR13C0062I2 (fr) Compositions pharmaceutiques comprenant du dextromethorphan et de la quinidine pour traiter des troubles neurologiques
MA26709A1 (fr) Compositions pharmaceutiques de celecoxib, leurs procedes de preparation et methodes de traitement les utilisant
AP1697A (en) Azabicycloalkanes as CCR5 modulators.
MA30655B1 (fr) Composes organiques.
EA200100872A1 (ru) Композиция валдекоксиба
WO2002099055A3 (fr) Cip comme modificateurs de la voie p53 et methodes d'utilisation associees
EP2101757A4 (fr) Composé pour le traitement ou la prévention de maladies en relation avec la prostate et compositions pharmaceutiques de système d'administration par le colon contenant ce composé
LT2526771T (lt) Brutono tirozinkinazės inhibitoriai
TR200101103T2 (tr) CGMP PDE-İnhibitörü içeren kontrollu serbest bırakılan farmasötik formülasyonlar
CY1109695T1 (el) Μικροοργανισμοι αποδομησης οξαλικου ή ενζυμα αποδομησης οξαλικου για την προληψη παθησης σχετιζομενης με οξαλικο
MA27509A1 (fr) Formulations a liberation prolongee contenant de la lamotrigine
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
ME00578A (en) Use of gastrointestinal lipase inhibitors
WO2006021160A8 (fr) Système de relargage de médicament auto-émulsifiant à base de butylbenzènephtaléine, méthode de préparation et applications d’un tel système
PT1358177E (pt) Tratamento de desordens afectivas atraves da accao combinada de um agonista do receptor nicotinico e uma substancia manoaminergica
MA27021A1 (fr) Sel consistant en citrate de 5,8,14-triazatetracyclo(10.3.1.0 .0 ) -hexadeca-2(11),3,5,7,9- pentaene et compositions pharmaceutiques le contenant
CY1108953T1 (el) Φαρμακευτικη φορμουλα περιλαμβανουσα παραγωγο πυριμιδινης α1 επιχρισμενο με εντερικο πολυμερες
WO2003105753A3 (fr) Procedes et compositions pour la greffe de boucles fonctionnelles dans une proteine